Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan and Fludarabine Conditioning for Allogeneic HCT in Acute Leukemia
NCT00253513Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2005
- Primary completion
- Oct 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Number of Patients Experiencing Regimen-related Toxicity Events at 2 years and Number of Patients Experiencing Graft Failure at 42 days. Started Jun 2005; status: completed.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00253513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253513.